Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.

Inclusion Criteria:

* Male or Female age \>/= 18 years of age
* Life expectancy \>/= 12 weeks
* Histologically or cytologically confirmed diagnosis of HCC, unresectable advanced or metastatic
* Liver function status of Child-Pugh class A. Child-Pugh status based on clinical findings and laboratory results during the screening period
* Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1
* Patients must have at least one naïve (not previously treated by locoregional therapy) uni-dimensional measurable lesion by CT or MRI according to RECIST 1.1
* Adequate bone marrow, liver and renal function

Exclusion Criteria:

* Previous or concurrent cancer other than HCC, except for cervical carcinoma in situ, basal cell carcinoma, superficial bladder tumors.
* History of cardiac disease: Congestive heart failure (CHF), unstable angina, arrhythmias, Uncontrolled hypertension
* Clinically significant GI bleeding (CTCAE grade 3 or higher) within 30 days
* Renal failure requiring hemo- or peritoneal dialysis
* Known human immunodeficiency virus (HIV) infection
* Known history or symptomatic metastatic brain or meningeal tumors
* History of organ allograft.
* History of interstitial lung disease (ILD).
* Excluded previous therapies and medications:

  * Prior use of systemic anti-cancer treatment for HCC including cytotoxic chemotherapy, targeted agents, or any experimental therapy
  * Radiotherapy within 4 weeks prior to start of study treatment
  * Any other investigational agents within 4 weeks from the first dose of study treatment
  * Major surgery within 4 weeks of start of study
  * Concomitant use of strong inhibitors and strong inducers of CYP3A4